XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.22.2.2

CEO SEPARATION AGREEMENT | 9 Months Ended
--- | ---
Sep. 30, 2022
CEO SEPARATION AGREEMENT [Abstract] |
CEO SEPARATION AGREEMENT |
7) | CEO SEPARATION AGREEMENT
On May 24, 2022, Dr. Howard J. Federoff resigned as the Company’s Chief Executive Officer and President effective May 26, 2022. In connection with Dr. Federoff’s resignation, the Company entered into a Separation Agreement and General Release with Dr. Federoff (the “Separation Agreement”), pursuant to which Dr. Federoff resigned from his positions as Chief Executive Officer and as an officer, director and employee of the Company and all subsidiaries. Dr. Federoff’s resignation from the Board was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In consideration for Dr. Federoff’s execution of the Separation Agreement and non-revocation of a waiver and release of claims relating thereto, Dr. Federoff will receive following benefits under the Separation Agreement:
| ● | a lump sum cash severance benefit in the amount of $0.2 million, representing Dr. Federoff’s target bonus for 2022;
| ● | payment of Dr. Federoff’s annual base salary for a period of twelve months after the expiration of the applicable revocation period (the “Separation Period”), for a total gross amount equal to $0.5 million;
| ● | payment of Dr. Federoff’s premiums for continued health benefits provided under COBRA for the Separation Period;
| ● | full acceleration of the vesting of all outstanding options (with the exception of the Milestone Grant (as defined below) options) that would have vested during the Separation Period, and such options, together with outstanding options that vested prior to the separation date, representing collectively approximately 76,000 shares of common stock, may be exercised for a period of thirty-six months after the separation date (see Note 11 for modification accounting impact);
| ● | acceleration and vesting of 25/36 th of the Milestone Grant options, representing collectively approximately 21,000 shares of common stock, may be exercised for a period of thirty-six months after the separation date (see Note 11 for modification accounting impact); and
| ● | a lump sum cash severance benefit in the amount of $0.1 million, representing the value Dr. Federoff would have received if he was entitled to receive a settlement of a pro rata portion of his performance restricted stock units through the expiration of the Separation Period, assuming the performance metrics were waived and assuming a per share value of $16.20.
The Separation Agreement also includes certain other customary representations, warranties and covenants of Dr. Federoff, and provides for reimbursement of certain expenses incurred by Dr Federoff. The Separation Agreement supersedes all other agreements or arrangements between Dr. Federoff and the Company regarding the subject matter of the agreement, including those with respect to severance payments and benefits.

X
- References No definition available. + Details
Name: | erna_CEOSEPARATIONAGREEMENTAbstract
Namespace Prefix: | erna_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure pertaining to chief executive officer separation agreement. + References No definition available. + Details
Name: | erna_ChiefExecutiveOfficerSeparationAgreementTextBlock
Namespace Prefix: | erna_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration